Piper Sandler downgraded Pacira Biosciences to Neutral from Overweight with a price target of $11, down from $42, following the company’s announcement that the U.S. District Court for the District of New Jersey ruled that its patent on Exparel is invalid. The firm says the shares are difficult to recommend amid the potential of an at-risk launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira down 48% after court finds Exparel ‘495 patent not valid
- Pacira trading resumes
- Pacira reports District Court found company’s ‘495 patent not valid
- Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
- Pacira trading halted, volatility trading pause